SOURCE: AtCor Medical Holdings Ltd.

October 13, 2008 11:12 ET

AtCor Medical Signs New $0.9m Pharmaceutical Trial Contract

US $3.7m in New Contracts in Past 130 Days

ITASCA, IL--(Marketwire - October 13, 2008) - AtCor Medical (ASX: ACG), the developer and marketer of the SphygmoCor® system which measures central blood pressures and arterial stiffness non-invasively, today announced that it has signed a new agreement to supply SphygmoCor® systems and clinical trial support services to a leading international pharmaceutical company. The minimum total value of this contract is US$930,000, the majority of which will be recognized in the current financial year. This new order brings the minimum total value of pharmaceutical trial contracts secured by AtCor in the past 130 days to over US $3.7 million.

Duncan Ross, CEO of AtCor Medical, said: "We continue to execute on our strategy in pursuing the pharmaceutical clinical trials market. This new contract is not only evidence of the increasing importance of SphygmoCor as a tool for understanding drug efficacy and mechanisms of action in pharmaceutical clinical trials but also reinforces its emerging importance as a drug therapy management tool in clinical practice. We look forward to continuing to build mutually beneficial relationships with our growing list of pharmaceutical trial customers."

Mr. Ross added, "The growing use of SphygmoCor systems in clinical trials and the increasing volume of publications concerning central blood pressures and arterial stiffness indicate a move toward establishment of a new standard for cardiovascular risk assessment and management. Our rapid revenue growth is also a clear indication of the defensive nature of the healthcare sector in a challenging macro economic environment."

About AtCor Medical

AtCor Medical develops and markets products for the early detection of cardiovascular risk and management of cardiovascular disease. Its technology allows researchers and clinicians to measure central blood pressure non-invasively. The company's SphygmoCor® system visibly identifies the effects of reflected blood pressure in the central aortic pressure wave, effects which cannot be detected with standard blood pressure monitoring. More than 1,700 SphygmoCor® systems are currently in use worldwide at major medical institutions research institutions and in various clinical trials with leading pharmaceutical companies, and the company's technology have been featured in over 400 peer-reviewed studies published in leading medical journals. AtCor has operations in Australia, the United States, and Europe. For further information, please visit our web site at

Contact Information

  • Contact info:
    Larry Watts
    AtCor Medical